• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Shattuck Labs, Inc. - Common Stock (NQ: STTK )

    3.720 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 3.720
    Bid (Size) 3.530 (5)
    Ask (Size) 3.900 (6)
    Prev. Close 3.720
    Today's Range 3.720 - 3.720
    52wk Range 1.330 - 11.76
    Shares Outstanding 42,122,778
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
    Via Benzinga
    Assessing Shattuck Labs: Insights From 7 Financial Analysts
    Via Benzinga

    Performance

    YTD
    -50.79%
    -50.79%
    1 Month
    +5.68%
    +5.68%
    3 Month
    -0.80%
    -0.80%
    6 Month
    -58.39%
    -58.39%
    1 Year
    +141.56%
    +141.56%

    More News

    Read More
    STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Assessing Shattuck Labs: Insights From 6 Financial Analysts
    Via Benzinga
    Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Announces Participation in Upcoming March Conferences
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
    From Shattuck Labs, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.